Clinical trial · Observational
Observational Cohort Study of Advanced Non-small Cell Lung Cancer (CAPTRA-LUNG)
NCT03334864CI-TRIAL-00069498unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Investigators propose to establish and maintain a cohort of patients with advanced non-small cell lung cancer, and to assess the treatment pattern, host genetic, and clinical factors which influence the prognosis and survival, as well as the interaction among these factors on disease diagnosis and treatment, short and long-term outcomes. Study type: Observational (Patient Registry) Study design: Observational Model: Cohort Time Perspective: Prospective and retrospective
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (5)
- label
- I Retrospective cohort
- description
- Diagnosis of advanced non-small cell lung cancer from 2012-2016
- label
- II Prospective cohort
- description
- Advanced non-small cell lung cancer with driver gene mutations
- label
- III Prospective cohort
- description
- Non-small cell lung cancer in immuno-therapy;
- label
- IV Prospective cohort
- description
- Non-small cell lung cancer with wild-type driver gene or unknown driver gene status;
- label
- V Prospective cohort
- description
- Advanced non-small lung cancer with wild-type gene treated with anti-Vascular Endothelial Growth Factor (VEGF) drug.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Cohort I: diagnosis of advanced non-small cell lung cancer from 2012-2016; * Cohort II: documented positive driver gene mutations; and diagnosis of advanced non-small cell lung cancer; * Cohort III: diagnosis of advanced non-small cell lung cancer and in immune-therapy; * Cohort IV: diagnosis of advanced non-small cell lung cancer, and with wild-type driver gene or unknown driver gene status; * Cohort V: treated with anti-VEGF drug in first line, diagnosis of advanced non-squamous and non-small cell lung cancer in 6 months before recruit; * Age\>18 years; * Provision of written informed consent. Exclusion Criteria: * not applicable
References
Publications (1)
- DERIVEDXu Y, Zhang L, Fang J, Wang Z, Li J, Li L, Ai B, Nie L, Mu X, Liang L, Zhang S, Zhang Y, Song Y, Song X, Wang Y, Xin T, Jin B, Wang X, Ding C, Wang M. Establishment of a prospective multicenter cohort for advanced non-small cell lung cancer in China (CAPTRA-Lung study). Thorac Cancer. 2018 Dec;9(12):1795-1800. doi: 10.1111/1759-7714.12865. Epub 2018 Sep 27. PMID 30264504